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ABSTRACT  
Gene therapy approaches using recombinant adeno-associated virus serotype 2 (rAAV2) and serotype 8 
(rAAV8) have achieved significant clinical benefits. The generation of rAAV Reference Standard 
Materials (RSM) is key to providing points of reference for particle titer, vector genome titer, and 
infectious titer for gene transfer vectors. Following the example of the rAAV2RSM, here we have 
generated and characterized a novel RSM based on rAAV serotype 8. Production of the rAAV8RSM was 
carried out using transient transfection and the purification was based on density gradient 
ultracentrifugation. The rAAV8RSM was distributed for characterization along with standard assay 
protocols to sixteen laboratories worldwide.  Mean titers and 95% confidence intervals were determined 
for capsid particles (mean, 5.50x10
11
 pt/ml; CI, 4.26x10
11
 to 6.75x10
11
 pt/ml), vector genomes (mean, 
5.75x10
11
 vg/ml; CI, 3.05x10
11
 to 1.09x10
12
 vg/ml), and infectious units (mean, 1.26x10
9
 IU/ml; CI, 
6.46x10
8
 to 2.51x10
9
 IU/ml). Notably, there was a significant degree of variation between institutions for 
each assay despite the relatively tight correlation of assay results within an institution. This outcome 
emphasizes the need to use RSMs to calibrate the titers of rAAV vectors in preclinical and clinical studies 
at a time where the field is maturing rapidly. The rAAV8RSM has been deposited at the American Type 
Culture Collection (VR-1816) and is available to the scientific community.  
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INTRODUCTION 
 
Remarkable clinical successes have been achieved in humans using recombinant adeno-associated viral 
(rAAV) vectors for hemophilia B, Leber Congenital Amaurosis (LCA) and lipoprotein lipase deficiency 
(LPLD) among other diseases (Bainbridge et al., 2008; Gaudet et al., 2013; Maguire et al., 2008; Manno 
et al., 2006; Nathwani et al., 2011). AAV serotype 2 is so far the best characterized and most used 
serotype for gene transfer studies but other AAV serotypes with more efficient gene delivery profiles for 
specific tissues are currently in human trials and their use will likely increase. One example is the clinical 
trial for hemophilia B using rAAV serotype 8 that has shown long-term expression of the transgene by the 
liver with significant clinical benefit (Nathwani et al., 2011). The market authorization by the European 
Medicine Agency in 2012 of Glybera
®
, a rAAV1 vector for the treatment of LPLD patients, was a 
milestone in the field of gene therapy and prompted many pharmaceutical companies to move into this 
field (Bryant et al., 2013). 
 As the first reference standard initiative in the viral vector gene therapy field, an Adenovirus 
Reference Material Working Group (ARMWG) was established and generated a human adenovirus 5 
Reference Standard Material (ATCC
®
 VR-1516) in 2002 (Hutchins, 2002). A similar need was 
recognized associated with the use of rAAV relating to the inability to calibrate vector doses administered 
by different investigators to animals and humans.  The need for reference standard materials (RSMs) for 
AAV vectors was recognized by the research community and an AAV Reference Standard Working 
Group was established and committed to the development of a rAAV2 Reference Standard Material 
(rAAV2RSM) (Snyder et al., 2002).  The AAVRSM Working Group is a volunteer organization and 
comprises members from both industry and universities, under the guidance of the FDA and NIH 
(Moullier et al., 2008;2012). The AAVRSM Working Group decided in 2002 that the first AAV reference 
standard material had to be based on the prototypical AAV serotype 2. Thus, the rAAV2 Reference 
Standard Material was produced by co-transfection of HEK293 cells with an AAV2 genome/hGFP 
transgene plasmid and a second plasmid encoding the AAV2 replication and capsid proteins, and was 
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purified by sequential rounds of column chromatography (Potter et al., 2008). The rAAV2RSM was 
characterized by 16 laboratories worldwide, the data was published and this material is available for the 
scientific community through the American Tissue Culture Collection (ATCC, VR-1616) (Lock et al., 
2010). Following this example, another effort was initiated by the AAVRSM Working Group in 2008 to 
generate a novel RSM based on serotype 8 (Gao et al., 2002).  The rAAV8RSM Working Group included 
members who participated on the AAV2RSM effort from industry and academia, from Europe, USA and 
Japan (Moullier et al., 2008). The rAAV8RSM was initiated in the framework of the European 
CLINIGENE Network of Excellence. The manufacturing of the rAAV8RSM was carried out in Europe 
by two laboratories (Atlantic Gene Therapies at Nantes, France and the Center of Animal Biotechnology 
and Gene Therapy at the Universitat Autonoma de Barcelona, Spain) and the characterization of the 
material involved 16 laboratories worldwide (coordinated by the University of Florida and the University 
of Pennsylvania). The rAAV8RSM is a pseudotyped AAV2 genome vector with capsid serotype 8 (Gao 
et al., 2002) expressing the GFP protein. To harmonize the two reference standards, the rAAV8RSM 
contains the same vector genome that was used for the rAAV2RSM. The vector was also produced by co-
transfection of HEK293 cells but the purification step differed from the rAAV2RSM, as it was purified by 
density ultracentrifugation using an optimized cesium chloride (CsCl) gradient-based protocol (Ayuso et 
al., 2012) and formulated in dPBS at a target concentration of >10
11 
vg/ml in cryovials frozen at EFS-
Atlantic Bio-GMP (Nantes, France). The protocols for the characterization were based on the previously 
developed consensual protocols for the rAAV2RSM but adapted to serotype 8 (www.lgcstandards-
atcc.org/Standards/Standards_Programs/ATCC_Virus_Reference_Materials). The rAAV8RSM 
characterization assays performed by the 16 laboratories included:  (i) capsid titer by enzyme-linked 
immunosorbent assay (ELISA); (ii) vector genome titer by quantitative polymerase chain reaction 
(qPCR); (iii) infectious titer by medium tissue culture infective dose (TCID50) with qPCR readout and; 
(iv) purity by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE). The AAV8RSM 
was also tested for sterility, endotoxin, and mycoplasma.  Altogether this international effort led to the 
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generation of more than 4040 vials of a rAAV8RSM that is stored at ATCC (N° VR-1816) and is 
available to the community. 
Finally, to cross-validate the use of the AAVRSMs, we conducted a side-by-side comparison of 
rAAV2RSM vs rAAV8RSM in terms of vector genome titration and capsid content using non-serotype 
dependent techniques. The data generated by 4 laboratories within the AAV8RSM Working Group were 
in agreement with the mean values reported by the community for the rAAV2RSM (Lock et al., 2010) 
and the rAAV8RSM (data from this paper).  
 
RESULTS 
 
rAAV8RSM manufacturing and pre-distribution quality control  
The manufacturing of the rAAV8 Reference Standard Material (rAAV8RSM) was carried out by two 
laboratories that harmonized their production protocols, i.e. Atlantic Gene Therapies –UMR 1089 in 
Nantes (France) and the Center of Animal Biotechnology and Gene Therapy (CBATEG) at the 
Universitat Autonoma de Barcelona (UAB) (Spain).  
The rAAV8RSM is a rAAV vector serotype 8 (Gao et al., 2002) produced using a HEK293 transfection-
based protocol. HEK293 cells were amplified from a cGMP master cell bank and transfected by the 
vector plasmid pTR-UF11 (Burger et al., 2004), the same plasmid used to generate the rAAV2RSM 
(Lock et al., 2010; Potter et al., 2008) and the pDP8 helper plasmid (see material and methods). Twelve 
sublots of rAAV8RSM were produced and purified in France and 15 sublots in Spain. The protocol 
followed was previously described (Ayuso et al., 2010). Since it was known that than up to 80% of 
functional rAAVs from serotype 8 are released into cell culture supernatant (Vandenberghe et al., 2010), 
the cell pellet was discarded and the supernatant was processed by PEG-precipitation and subsequently 
purified by double Cesium-Chloride (CsCl) gradient ultracentrifugations followed by a dialysis step 
against Phosphate Buffered Saline containing Calcium and Magnesium (dPBS) (Figure 1).  
In-process quality control (QC) testing was performed on each sublot for purity, identity and vector 
genome titer to meet predetermined minimum specifications: (i) > 85% purity and the correct AAV 
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capsid protein banding pattern and (ii) vector genome titer >10
12
 vg/ml. Silver staining of SDS-PAGE gel 
of each sublot is shown in Supplementary Figure 1. The sublot BCN7 was discarded due to the presence 
of significant impurities (Supplementary Figure 1b). Identity of the VP proteins was verified on a few 
sublots by Western blot analysis using anti-capB1 or anti-AAV2 polyclonal antibodies (Supplementary 
Figure 1c). The Western Blot analysis using a polyclonal anti-AAV2 antibody suggests that the extra-
band migrating below VP3 revealed by silver stain (Supplementary Figure 1a) is a cleavage product of the 
capsid proteins (Van Vliet et al., 2006). The vector genome titer was determined in each sublot by dot-
blot and/or qPCR using the rAAV2RSM as a control (Supplementary Table 1 and Supplementary Table 
2). The sublot BCN4 was discarded due to the vector genome titer being below the target concentration. 
Accordingly, a total of twenty-five selected sublots were then combined and diluted with dPBS to 
generate the purified bulk. The purified bulk was then tested for vector genome titer, bioburden, 
mycoplasma and endotoxin prior to fill and finish (Table 1). A total of 4088 vials containing 0.125 ml 
were subsequently filled into 1.2 ml polypropylene low-binding cryovials. Vector genome and infectious 
titers (transducing units) as well as microbiological tests were performed on the final product before 
shipment to the American Type Culture Collection (catalog number VR-1816) (Table 1).  In summary, 
we generated about 500 ml of rAAV8RSM with an estimated titer of 6x10
11 
vg/ml resulting in a total 
vector amount of >3x10
14 
vg. 
 
Characterization of the rAAV8RSM 
For the characterization of the rAAV8RSM we took advantage of the experience previously gained when 
the community characterized the rAAV2RSM and therefore we used similar protocols and reagents 
adapted to the AAV8 serotype. The assays chosen for the rAAV8RSM characterization included: (i) 
confirmation of the serotype and capsid particle titer by an AAV8 specific enzyme-linked immunosorbent 
assay (ELISA; Progen) (Sonntag et al., 2011); (ii) vector genome titer by quantitative polymerase chain 
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reaction (qPCR); (iii) infectious titer by tissue culture infective dose (TCID50) with qPCR readout; (iv) 
evaluation of the purity, capsid subunit stoichiometry, and chemical integrity of the capsid by sodium 
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE).  
Key reagents used for the characterization of the rAAV8RSM were already used for the rAAV2RSM 
characterization and are available from ATCC. For both genome and infectious titers assays, a qPCR 
primer/probe set directed to the SV40 polyA sequence and a dilution series specific to the RSM were 
selected.  For the purity and identity assay, commercially available assay reagents with the highest 
sensitivity were suggested.  Using these reagents, the protocols were adapted for rAAV8 vectors and were 
beta tested at the University of Pennsylvania Gene Therapy Program against both in-house standards and 
the rAAV8RSM itself. The finalized protocols were posted on the ATCC website 
(http://www.lgcstandards-
atcc.org/en/Standards/Standards_Programs/ATCC_Virus_Reference_Materials/AAV8_Additional_Infor
mation.aspx).  
The rAAV8RSM (ATCC VR-1816) was distributed along with the required reagents and handling 
instructions to 16 laboratories worldwide (Table 2), which volunteered to conduct one or more of the 
characterization assays.  The characterization phase of the rAAV8RSM proceeded from 2011-2013.  
Upon receipt, the RSM was evaluated by the sixteen testing laboratories according to the posted 
protocols, and the data were recorded on the assay spread sheets provided, which contained the necessary 
calculations for titer determination.  
 The raw data, which emerged from the testing laboratories for the three quantitative titer assays 
(Table 3) were statistically analyzed to determine true mean titer values and 95% confidence intervals. 
The distribution was first visualized as histograms (Supplementary Figure 2) and it was noted that the 
data did not appear to be normally distributed.  Since valid estimation of the mean and confidence interval 
relies on an underlying normal distribution, it was clear that some form of transformation was warranted.  
Common statistical transformation methods employed are square root, natural log and log base 10. 
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Therefore, means and intervals were calculated on the transformed data and the results were then back-
transformed to the original measurement scale; the data for each assay were processed in this way using 
all three transformations.  Analysis of the mean and median (for normally distributed data these two 
values are the same) and skewness and kurtosis estimates confirmed that the transformations were 
performing as expected and were similar to those obtained for the AAV2RSM (Supplementary Table 3). 
Supplementary Figure 3 shows the results of the most successful transformations for each assay as 
quantile-quantile plots.  In this analysis the quantiles (ie 5%, 10% etc) obtained from the transformed data 
were compared to the quantiles that would be expected for a normal distribution.  A line that extends 
through the 25
th
 and 75
th
 quantile is shown on the plots and the nearer the points are to this line, the more 
normal are the data distribution. The capsid particle titer assay data appeared normally distributed without 
the need for transformation (Supplementary Figure 3A).  For the vector genome titer and for the 
infectious titer, a log base 10 transformation appeared the most appropriate (Supplementary Figure 3B,C). 
The transformed data are summarized in Supplementary Table 4.  For each assay, two and three standard 
deviation limits were calculated corresponding to nominal 95% and 99.7% confidence bounds on 
individual values.  Any test result lying outside of the three standard deviations was considered to be an 
outlier.  Using this criterion only one test result from the particle titer assay and one test result from 
infectious titer were determined to be outliers and were removed from the analysis (Table 3, in red); the 
values reported in Supplementary Table 4 exclude these data points.   
 An assumption we made when calculating the mean values and confidence intervals is that each 
test result is independent of another, however this assumption does not take into account that all 
institutions submitted duplicate (and in some cases triplicate) test results for the assays.  To assess the 
degree of correlation between samples, Pearson coefficients were determined for the first two duplicate 
samples per institution and the coefficients obtained were 0.71 for vector particle titer, 0.96 for vector 
genome titer and 0.97 for infectious units titer.  These results indicated that there was a significant 
correlation within institution and that the assumption that each result is independent was violated.  To 
account for this correlation, the transformed data were modeled, using a linear random effect modeling 
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approach (Littell et al., 2006).  This allows for a unique component associated with each institution to be 
included in the model, under the assumption that these institutional random effects have a mean of zero. 
When the correlation within an institution is accounted for, the precision of the mean estimate as 
illustrated by the width of the 95% confidence interval is decreased (Table 4).  Taking the transformed, 
modeled data as the true estimate of the mean we reached the following determinations for the 
rAAV8RSM: the mean particle titer is 5.5 x 10
11
 pt/ml with 95% confidence that the true value lies in the 
range 4.26 x 10
11
 to 6.75 x 10
11
 pt/ml; the mean vector genome titer is 5.75 x 10
11
 vg/ml with 95% 
confidence that the true value lies in the range 3.05 x 10
11
 to 1.09 x 10
12
 vg/ml and the mean infectious 
titer is 1.26 x 10
9
 TCID50 IU/ml with 95% confidence that the true value lies in the range 6.46 x 10
8
 to 
2.51 x 10
9
 TCID50 IU/ml (Table 4).  
Interestingly, the vector genome titer was very similar to the vector particle titer indicating that the 
AAV8RSM is virtually devoid of empty particles. This finding is consistent with the CsCl gradient 
purification protocol used in the production of the rAAV8RSM that efficiently separates empty vs full 
particles (Ayuso et al., 2010).  
The DNA content of the AAV8RSM was extracted and native agarose gel electrophoresis was used to 
confirm the homogeneity and the size the vector genome (expected genome size of 4.3 Kb) 
(Supplementary Figure 4).  
The purity of the rAAV8RSM was assessed by SDS–PAGE analysis.  The RSM was examined under 
both denaturating and non-denaturating conditions using Sypro ruby and silver stains (Figure 2).  Under 
denaturating conditions all proteins including the denatured AAV8 capsids are expected to enter the gel 
and impurities would be detected as protein bands other than the capsid proteins VP1, VP2 and VP3.  
Under non-denaturating conditions the capsid would remain intact and would not be expected to enter the 
resolving gel whereas impurities would enter the gel; proteins, which previously co-migrated with the 
capsid proteins on denaturating gels would thus be detected.  Silver nitrate staining was included since it 
is capable of detecting DNA, lipid and carbohydrate impurities as well as nanogram levels of protein 
(Weiss et al., 2009).  Sypro ruby is a protein-specific fluorescent dye, which has sensitivity close to that 
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of silver stain (Rabilloud et al., 2001; Weiss et al., 2009).  In each case the rAAV8RSM was analyzed 
alongside an internal laboratory standard AAV vector. The consensus data from the 14 testing 
laboratories which carried out the purity test estimated that the rAAV8RSM was greater than 99 % pure 
and confirmed that VP1, VP2 and VP3 co-migrated with the AAV capsid proteins of the internal vector 
standards (Figure 2 and data not shown).   
 
Comparison of rAAV2RSM vs rAAV8RSM 
Having an increasing repertoire of AAV serotypes entering the clinical arena is encouraging for the field 
of AAV-mediated gene transfer. However, the characterization of the AAV preparations and the 
comparison of data between studies will become more complex without the appropriate use of common 
standards. As an example, here we have compared the vector genome titers and the capsid content of 
rAAV2RSM and rAAV8RSM using non-serotype-dependent techniques. This comparative study was 
performed in four institutions independently within the AAV8 RSM Working Group. The vector genome 
titer was measured by qPCR according to the SOPs written for the rAAV8RSM and using the primers and 
probe targeting the SV40 polyA. Of note, these experiments were performed before the collection of the 
data from the 16 laboratories and the statistical analysis shown in Table 4. The vector genome titers of the 
rAAV8RSM obtained by the four laboratories were within the 95% confidence limits shown in Table 4, 
however, while the titers for the rAAV2RSM were within the confident limits in two laboratories, in two 
other institutions they were slightly lower than the lower confidence limit for the rAAV2RSM (2.7x10
10
 
to 4.75x10
10 
vg/ml). Interestingly, the use of the rAAV2RSM as a control evidenced a significant 
deviation of the titration in the first assay conducted in Institution C (Table 5, in red) and therefore the 
experiment was repeated. Altogether, these data indicate that the same protocol for vector titration by 
qPCR could be used independently of the serotype, however the inclusion of one or more RSMs was 
crucial to obtain confident titers and avoid significant deviations. 
Although the vector genome titer is the most widely used for dosing rAAV in clinical trials, it is also 
believed that total capsid content plays a critical role in the immune responses against the therapeutic 
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vector (Manno et al., 2006; Mingozzi et al., 2013; Mingozzi et al., 2007; Mingozzi et al., 2009). Capsid 
titer can be measured by serotype-specific ELISA, as shown for rAAV2 (Grimm et al., 1999; Lock et al., 
2010) and here for rAAV8, however this assay is only available for several other serotypes e.g. AAV9, 
AAV1/6, AAV4 and AAV5 (Kuck et al., 2007; Sonntag et al., 2011) and it could be difficult to develop 
specific antibodies for hybrid/chimeric serotypes. Here, we have used SDS-PAGE gel and Sypro staining 
to semi-quantitate the capsid content of two different serotypes of AAV, in this case the rAAV2RSM and 
the rAAV8RSM. The same four institutions mentioned above performed this experiment. The same 
AAV8 vector stock used for the standard curve of the ELISA kit (WL217S) was used here as a control, 
with the exception that here the vector was used in its native form while the ELISA standard is supplied 
lyophilized. Notably, this experiment was performed before the collection of the data from the 16 
laboratories and the statistical analysis shown in Table 4, thus the rAAV2RSM sample was loaded on the 
gel according to the previously published capsid titer of 9.1x10
11
 pt/ml (Lock et al., 2010), but the 
rAAV8RSM was loaded based on the capsid titer obtained in each institution using the specific AAV8 
ELISA kit. The amount of capsid of the rAAV2RSM was in agreement with the dose of WL217S used as 
standard and, importantly, the amount of capsids loaded on the gel of the rAAV8RSM was similar to the 
rAAV2RSM (Figure 3, and data not shown). Of note, the amount of vector genomes loaded on the SDS-
PAGE gel were much higher for the rAAV8RSM than for the rAAV2RSM, since the rAAV2RSM had a 
much higher amount of empty capsids (Lock et al., 2010). These data indicate that both ELISAs (AAV2 
and the AAV8) generate comparable titers in terms of capsids/ml. These data also indicate that SDS-
PAGE, a non-serotype-dependent technique is useful to estimate the capsid content of rAAV vectors 
when specific antibodies (and therefore an ELISA) are not available.    
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DISCUSSION 
More than 100 clinical trials using different serotypes of rAAV have been registered up to 2014 
(http://www.wiley.com/legacy/wileychi/genmed/clinical/). Recently, a gene therapy product based on 
rAAV (Glybera
®
) has been granted with the marketing authorization from the European Medicine 
Agency (EMA) opening new dynamics and business models for rAAV-based therapeutics (Bryant et al., 
2013). Despite the extensive use of rAAV vectors, there has been a lack of standardization and inability to 
compare titer values for vectors made and tested within the same laboratory and within different ones. For 
this reason, an AAV2 Reference Standard Working group was formed in 2002 with the mission to 
generate and characterize a rAAV2 Reference Standard Material (rAAV2RSM) (Moullier et al., 2008; 
Potter et al., 2008; Snyder et al., 2002). Sixteen laboratories participated in the characterization and the 
consensus titers (and other characterization data) of rAAV2RSM were compiled and published (Lock et 
al., 2010). However, vector systems based on novel rAAV serotypes (Gao et al., 2004; Gao et al., 2002) 
are being developed rapidly and the scientific community raised the question of whether other RSM will 
be needed. An AAV8RSM Working Group including industry and academic institutions from 10 
countries, and sixteen laboratories was established in 2008 to generate and characterize an AAV8RSM 
(Ayuso et al., 2012; Moullier et al., 2008;2012). Most of the members had participated in the AAV2RSM 
Working Group, which facilitated the effort and maintained continuity. Here, we have described the 
manufacturing and the characterization of a novel reference for the field, namely the rAAV8RSM. The 
upstream process for the rAAV8RSM was based on co-transfection of HEK293 cells, as for the 
rAAV2RSM, but the downstream process was based on density gradient ultracentrifugation, which differs 
from the rAAV2RSM that was purified by chromatography (Potter et al., 2008).  Using the gradient 
purification protocol we obtained a rAAV8RSM that is virtually free of empty capsids, which is a major 
difference compared with rAAV2RSM that contain more than 95% empty particles (Lock et al., 2010). 
Another significant difference between the two standards is the ratio of vector genomes/infectious 
particles; this ratio is 7.5 for the rAAV2RSM but >400 for rAAV8RSM. We hypothesize that this is due 
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to the poor ability for rAAV8 to transduce cells in vitro, as already described (Gao et al., 2002; 
Mohiuddin et al., 2005).  Identifying cell lines that can be efficiently infected with different AAV 
serotypes and helper viruses is greatly needed, as this impacts not only the infectious titer values but also 
the particle to infectious ratio and transgene expression assays. However, as long as similar vector 
genome/infectious particle ratios are obtained for different lots of the same serotype, thus demonstrating 
lot-to-lot product consistency, and the ratios can be correlated to vector potency, then the vector lots can 
be considered suitable for use. 
The characterization of the rAAV2RSM demonstrated a high degree of variation between institutions for 
each assay despite the relatively tight correlation of assay results within an institution.  Here, we have 
observed exactly the same outcome during the characterization of the rAAV8RSM. This poor degree of 
inter-laboratory precision and accuracy is very illuminating, in light of the major effort to standardize the 
assays by providing detailed protocols and common reagents.  In addition, several laboratories had 
already performed the same assays in the frame of the rAAV2RSM project and the AAV2RSM was made 
available to the community before launching the characterization campaign of the rAAV8RSM.  
Vector genome titer is the most commonly used titer to dose patients in clinical trials. Here, we observed 
a very significant variation of the vector genome titer by qPCR of the rAAV8RSM with the lowest titer 
being 4.6x10
10 
vg/ml and the highest titer 4.7x10
12 
vg/ml (Table 3). Having a two-log difference in the 
titer of the same rAAV material is a cause for concern considering that most of the clinical trials use 
doses within one log variation (Manno et al., 2006; Nathwani et al., 2011), and may reflect not only the 
qPCR variability itself (different PCR machines, different sources of PCR primers and probes, storage 
and handling of PCR reagents, preparation and spectrophotometry of plasmid standard curves), but also 
rAAV sample preparation and recovery. qPCR has become the method of choice for AAV genome 
titration due to its simplicity and relative robustness. However, as we note here, the assay is not without 
sources of variability.  As the field progresses, new and improved assays with greater degrees of precision 
are likely to emerge.  In this regard, an AAV vector genome quantitation method based upon droplet 
digital PCR has recently been described which yields improved intra- and inter-assay precision in 
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comparison with qPCR, as well as eliminating the need for a plasmid standard curve (Lock et al., 2014).  
Adoption of such techniques by the AAV gene therapy community may help to reduce the type of inter-
laboratory variation observed in this study.  
The data presented here stress, more than ever, the necessity to work towards the calibration of vector 
titers and to standardize dosage units within the field. Now, two different rAAVRSMs are available to 
help validate in-house quantitative assays at a time where the field is maturing rapidly. As an example, 
four independent laboratories within the AAV8RSM working group performed an experiment consisting 
in titrating simultaneously the rAAV2RSM and the rAAV8RSM using the same protocols and reagents. 
The utilization of rAAV2RSM as a control permitted one laboratory to discard one of the tests that 
produced significant biased results with the overall result that the final titer of the rAAV8RSM obtained 
fell within the confidence limits for all sixteen laboratories.  
Interestingly, the capsid titer for both rAAV2RSM and rAAV8RSM determined by a commercial ELISA 
was the parameter with the least variation, perhaps because the kit provided the reagents and internal 
controls. Also, the capsid titer determined by the ELISA for serotype 2 and for the serotype 8 are 
comparable as showed by a non-serotype dependent methodology (Table 5). Quantification of total capsid 
content is critical for clinical trials, since immune responses are clearly dependent on the vector capsid 
(Manno et al., 2006; Nathwani et al., 2011). The availability of ELISA methods and RSMs will help the 
field to better characterize vector preparations used in clinical trials. Even if an ELISA is not available for 
a specific serotype or chimeric AAV vector, it is possible to use other methods to measure total capsids, 
such as electronic microscopy (Materials and Methods and (Grimm et al., 1999), optical density (Sommer 
et al., 2003), or SDS-PAGE gel staining (Figure 3). rAAV2RSM and rAAV8RSM could be used to 
evaluate total capsid load for those alternative AAV serotypes. 
A stability monitoring program which tracks physical and infectious titers over time is ongoing for the 
AAV2RSM generated in 2006, and data from several years has been collected (data not shown). 
Similarly, the AAV8RSM Working Group will follow the stability of the AAV8RSM at regular intervals. 
 Page 17 of 50 
H
um
an
 G
en
e 
Th
er
ap
y
M
an
uf
ac
tu
rin
g 
an
d 
Ch
ar
ac
te
riz
at
io
n 
of
 a
 R
ec
om
bi
na
nt
 A
de
no
-A
ss
oc
ia
te
d 
V
iru
s T
yp
e 
8 
Re
fe
re
nc
e 
St
an
da
rd
 M
at
er
ia
l (
do
i: 1
0.1
08
9/h
um
.20
14
.05
7)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
18 
18 
 
Regulatory European (EDQM) and US (FDA CBER, OCTGT and DCGT) bodies have encouraged the 
AAV2RSM and AAV8RSM Working Group to generate and characterize reference materials and 
recommended the use of these standards to the sponsors of rAAV vector INDs and IMPDs. 
In summary, this manuscript describes the manufacturing and the characterization of a novel rAAV8RSM 
material deposited at ATCC under the reference VR-1816 that represents an important tool to better 
determine vector dosing units. Having validated and calibrated methods to determine rAAV titers of 
preclinical and clinical vectors will accelerate the development of rAAV-based medicines and will protect 
patients participating in future trials. 
 
 
 
  
 Page 18 of 50
H
um
an
 G
en
e 
Th
er
ap
y
M
an
uf
ac
tu
rin
g 
an
d 
Ch
ar
ac
te
riz
at
io
n 
of
 a
 R
ec
om
bi
na
nt
 A
de
no
-A
ss
oc
ia
te
d 
V
iru
s T
yp
e 
8 
Re
fe
re
nc
e 
St
an
da
rd
 M
at
er
ia
l (
do
i: 1
0.1
08
9/h
um
.20
14
.05
7)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
19 
19 
 
 
MATERIALS AND METHODS 
 
Reference Standard Material manufacturing 
Production and purification of the rAAV8RSM were carried out at Atlantic Gene Therapies –UMR 1089 
in Nantes (France) and the Center of Animal Biotechnology and Gene Therapy (CBATEG) at the 
Universitat Autonoma de Barcelona (UAB)(Spain). 
Production was initiated by co-transfection of a certified master cell bank of HEK293 cells (ABG-EFS, 
Nantes, France) in 5-chambers Corning Cellstacks (at Nantes) or Corning Roller Bottles (at Barcelone) 
with plasmid pTR-UF-11 (ATCC # MBA-331), containing the vector genome and hGFP expression 
cassette (Burger et al., 2004) and the pDP8 helper plasmid harboring the rep gene from AAV2, the cap 
gene from AAV8, the adenovirus helper genes E2A, E4, VA-RNA and the ampicillin resistance gene (N° 
PF478, Plasmidfactory, Bielefeld, Germany) using a calcium phosphate precipitation method.   Same lots 
of FBS (Hyclone-Thermo scientific, Waltham, MA), trypsin (PAA Laboratories GmbH, Linz , Austria), 
DMEM (PAA), Pen/Strep (PAA), PBS (PAA) and dPBS (PAA) were split between the two 
manufacturing sites.  
For the transfection, the complete medium (DMEM, 10% FBS, 1% Pen/Strep) was removed and replaced 
by transfection medium (DMEM, 2% FBS, 1% Pen/Strep) including the transfection mixture. After 6 to 
15 hours at 37°C and 5% CO2, the transfection medium was then removed and replaced by fresh 
exchange medium (DMEM, 1% Pen/Strep) prior to a 3 days incubation at 37°C and 5% CO2. The cells 
were harvested and centrifuged at 1500 g for 10 min at 4°C. The cell pellet was discarded and the 
supernatant was precipitated with PEG at a final concentration of 8% for a period of 15 hours to 3 days at 
5 +/- 3°C. Samples of these cells pellets from Nantes and Barcelona were tested for mycoplasma and 
found to be negative by PCR using the Mycotrace kit (PAA, ref : Q052-20). The PEG-precipitated 
supernatant was then centrifuged at 5,000 g for 45 min at 4°C. The supernatant was discarded and the 
PEG-pellet was resuspended in  Tris Buffer Saline (TBS) before benzonase digestion at 37°C for 30 min. 
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Following benzonase digestion, the viral suspension was centrifuged at 10,000 g for 10 min at 4°C and 
the vector-containing supernatant was loaded on a step density CsCl gradient (1.5 g/cm
3
 at the bottom and 
1.3 g/cm
3
 on top) in UltraClear tube for SW28 rotor (Beckman coulter, Brea, CA). The gradient was 
centrifuged at 28,000 rpm for 24 hours at 15°C. The full particles band was collected with a 10 ml syringe 
and transfered to a new UltraClear tube for SW41 rotor filled with 1.375 g/cm
3 
density CsCl. The 2nd 
gradient was centrifuged at 38,000 rpm for 48 hours at 15°C. The enriched-full particles band was then 
collected with a 10 ml syringe (the volume recovered for each run is indicated in Supplementary Tables 1 
and 2). The viral suspension was then subjected to 4 successive rounds of dialysis under slight stirring in 
a Slide-a-Lyzer cassette (Pierce, Rockford, IL) against dPBS (containing Ca and Mg). No other additives 
were included in the formulation buffer (dPBS).  
Each purified vector sublot was finally collected, sampled for vg titer and purity assay, and stored at <-
70°C in polypropylene low-binding cryovials.  
The specifications of the dPBS (PAA Laboratories) used as a formulation buffer were: 
pH 7.0-7.5 
Osmolality 240-320 mOsmol/Kg 
Endotoxin <1 EU/ml 
Composition: KCL 0.2 g/l; KH2PO4 0.2 g/l ; NaCL 8.00 g/l ; Na2HPO4 anhyd. 1.15 g/l; CaCl2-2H2O 0.132 
g/l; MgCL2-2H2O 0.1 g/l. 
 
rAAV8RSM Fill Finish and final Quality Control  
Fill finish and final quality control were carried out at EFS-ABG (Nantes, France), a European 
pharmaceutical site dedicated to ATMPs manufacturing. All of the sublots produced at Nantes and 
Barcelona (except two lots, as described in Result section) were combined and diluted to 200 ml in dPBS 
(see specifications and composition above). This purified bulk was subsequently tested for endotoxin (EP 
2.6.14), Mycoplasma (EP 2.6.7) and Bioburden (EP 2.6.12) by Vitrology Ltd, Glasgow, Scotland, and the 
vector genome titer was determined by qPCR at Atlantic Gene Therapies (Nantes, France), prior to final 
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formulation, sterile filtration and filling in an ISO5 cleanroom at EFS-ABG with environmental 
monitoring. The purified bulk was diluted with 325 ml of dPBS and was then sterile filtered using a 0.2 
μm PES filter (Sartorius). The filtered formulated bulk was then vialed in 14 sterile 50 ml conical tubes 
(Corning, Polypropylene 50 ml tubes, USP Class VI) stored at < -70°C. The sterile bulk was then filled 
into 4088 cryovials (Corning 1.2 ml polypropylene cryogenic vial, USP, class VI) with a volume of 0.125 
ml/vial using an electronic adjustable repeating pipette AutoRep (RAININ, Oakland, CA). Prior to 
storage at < -70°C, the vials were labeled according to ATCC requirements as follows: ATCC®, VR-
1816™, rAAV8-RSS– Reference Material, ABG[date] - 0.125 ml, Store at < -70°C – For research use 
only. Lot #03112010SP2pcg. 
Due to the number of vials (> 4000 vials), seven fill days were required. Each fill date is indicated on the 
label. At each filling session, the first and the last cryovial filled were transferred to Quality Control for 
further sterility assay. Thus, a total of 28 cryovials were submitted to sterility assay at Vitrology Ltd. The 
final product was submitted to preliminary tests for vector genome titer (qPCR SV40 and Dot Blot 
hybridization using a GFP probe), transducing titer and purity/identity (Silver Stained SDS-PAGE gel).  
A summary of QC performed on the purified bulk and on the final product is shown in Table 1. The SDS-
PAGE silver stain purity assay is shown in Supplementary Figure 5 and suggests that the AAV8RSM 
purity is similar to the control AAV2RSM one which was determined at 94% using SYPRO Ruby 
staining following SDS-PAGE (Lock et al., 2010). 
 
rAAV8 RSM handling.  
For rAAV8RSM characterization, each testing laboratory received two vials from ATCC on dry ice. 
Upon receipt both vials were stored frozen at -70 to -90
o
C. One vial was thawed at room temperature 
while mixing gently and then kept on wet ice. Within 1 hour of thawing, the infectious titer was 
conducted.  The remainder of the thawed vial was stored at 4
o
C and mixed gently upon use. Within 5 days 
of vial thaw, the particle titer, vector genome titer and purity/identity assays were performed. These steps 
were repeated for the second vial starting on a different calendar day.   
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See posted protocol: 
http://www.lgcstandards-
atcc.org/en/Standards/Standards_Programs/ATCC_Virus_Reference_Materials/AAV8_Additional_Infor
mation.aspx 
 
rAAV8RSM Characterization assays 
Brief descriptions of each characterization assay follow.  For those wishing to reproduce these assays, 
detailed protocols can be found at the links specified below or may be requested directly from M. Lock or 
R. Snyder. 
 
Particle titer.  The particle concentration was determined by each laboratory, using four separate 
dilution series from a single vial in the Progen AAV8 Titration ELISA (Progen Biotechnik GMBH, 
Article number PRAAV8), against a standard curve prepared from a previously titered rAAV8 
preparation (WL217S). The particle content of WL217S was determined by first spiking the preparation 
with the adenoviral reference material (ARM ATCC VR-1516, with a known particle concentration) and 
then obtaining images of the particles by electron microscopy. Due to the size difference between AAV 
and adenovirus the particles of each can be distinguished and counted on electron micrographs.  Several 
fields were counted and the average ratio of AAV particles to the internal ARM standard was used to 
compute the particle titer for WL217S. Briefly see posted protocol:  
http://www.lgcstandards-
atcc.org/~/media/AAV8_Information/AAV8%20RSM%20particle%20titer%20by%20ELISA.ashx 
 
Vector Genome titer.  The vector genome concentration was determined in duplicate, testing one 
replicate from each of two vials, by qPCR of serial dilutions of rAAV8RSM against a standard curve of 
plasmid pTR-UF-11 (ATCC MBA-331)(Burger et al., 2004). Some labs performed more than two tests 
for vector genome titrations (Table 3). See posted protocol:  
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http://www.lgcstandards-
atcc.org/~/media/AAV8_Information/AAV8%20RSM%20genome%20copy%20titration%20by%20QPCR.
ashx 
 
Infectious titer.   Serial ten fold dilutions of rAAV8RSM were made on HeLa RC32 cells (ATCC 
CRL-2972) (Tessier et al., 2001) and co-infected with Adenovirus type 5 (ATCC VR-1516).  72 
hours post infection total cell DNA was extracted and analyzed for AAV vector genome copies by qPCR. 
Input vector genomes were subtracted and TCID50 titers calculated according to the method of 
Spearman/Karber. See posted protocol: 
http://www.lgcstandards-
atcc.org/~/media/AAV8_Information/AAV8%20RSM%20Infectious%20titer%20assay.ashx 
 
Purity and identity. The purity and identity of the rAAV8RSM were evaluated by SDS 
polyacrylamide gel electrophoresis (SDS-PAGE), using SYPRO ruby (Invitrogen) or silver staining 
(SilverXpress; Invitrogen).   The AAV8 VP1, VP2, and VP3 capsid protein bands were evaluated for their 
stoichiometry and size.  Purity relative to non-vector impurities visible on stained gels was determined. 
See posted protocol:  
http://www.lgcstandards-atcc.org/~/media/AAV8_Information/AAV8_%20RSM_Identity-
Purity_Assay.ashx 
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Supplementary Material 
 
Supplementary Table 1. Vector genome titer of sublots produced at Nantes. 
Supplementary Table 2.  Vector genome titer of sublots produced at Barcelone. 
Supplementary Table 3.  Summary statistics for the untransformed and transformed variables. 
Supplementary Table 4. rAAV8 Reference Standard Material Titer Estimates after Transformation 
 
Supplementary Figure 1. Siver stained SDS-PAGE gel and western blot of sublots produced at Nantes 
and Barcelone. a) AAV8RSM sublots (Nantes), Silver Stained SDS-PAGE gel, 2.10x10
10
 vg/well. b) 
AAV8RSM sublots (Barcelone), Silver Stained SDS-PAGE gel, 5.10x10
9
 vg/well. c) Western blot 
analysis of few sublots produced at Nantes. On the left, Western blot using anti-capB1 antibody. On the 
right, Western blot using anti-AAV2 polyclonal antibody. 
 
Supplementary Figure 2: Histograms displaying the distributions of a) particle titer (pt/ml), b) vector 
genome titer (vg/ml), and c) infectious titer (iu/ml).  
 
Supplementary Figure 3: Quantile-quantile plots displaying sample versus normal quantiles of a) 
particles/ml, b) Log10 vector genomes/ml, and c) Log10 infectious units/ml.  Lines pass through the 25th 
and 75th quantiles.  
 
Supplementary Figure 4. Assesment of the AAV8RSM vector genome integrity by native agarose gel 
electrophoresis. Total DNA was extracted from AAV8RSM and about 4x10
10
 vg were loaded on a native 
agarose gel (central lane). After electrophoresis, the gel was stained with GelRed. ‘‘M’’ denotes marker 
lanes, which contains standards of sizes indicated at right of image.  
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Supplementary Figure 5. The rAAV2RSM and rAAV8RSM were run on SDS PAGE gels under 
denaturating conditions and then stained with silver staining.  
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Table 1. Quality control of intermediate and  final product 
 
Test item Tests Method Laboratory Results 
Purified 
Bulk 
Vector genome 
(vg/ml) 
qPCR UMR1089 5.7x1012 vg/ml 
Bioburden EP 2.6.12 SGS-Vitrology 0 cfu/ml 
Endotoxin EP 2.6.14 SGS-Vitrology <0,03 EU/ml 
Mycoplasma EP 2.6.7 SGS-Vitrology Negative 
Final 
Product 
Vector genome 
(vg/ml) 
qPCR UMR1089 6.4x1011 vg/ml 
Vector genome 
(vg/ml) 
Dot blot UMR1089 6.3x1011 vg/ml 
Transducing 
units  (TU/ml) 
Transduction 
of cells; GFP 
read out 
UMR1089 1.5x108 TU/ml 
Sterility EP 2.6.1 SGS-Vitrology sterile 
 
 
Table 1. Quality control of intermediate and final product 
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Table 2. rAAV8 Reference Standard Material Testing Laboratories 
Telethon Insitute of Genetics and Medicine, TIGEM, Naples, Italy 
Universitat Autonoma de Barcelona, Spain 
Research Institute at Nationwide Children’s Hospital, USA  
University of Florida, USA 
Atlantic Gene Therapies, France 
Genethon, France 
International Center for Genetic Engineering and Biotechnology (ICGEB), Italy 
German Cancer Research Center (DKFZ), Germany  
University of Pennsylvania, USA 
Jichi Medical University, Japan 
Sangamo BioSciences, USA 
University of Massachusetts Medical School, USA 
Universite Libre de Bruxelles, Belgium 
uniQure, The Netherlands  
Children’s Hospital of Philadelphia, USA 
Lausanne University Hospital, Switzerland 
 
 
Table 2.  rAAV8 Reference Standard Material Testing Laboratories 
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Table 3.rAAV8 Reference Standard Material raw characterization data 
Laboratory Replicate 
Particle 
titer 
(ELISA) 
(pt/ml) 
Genome 
titer 
(qPCR) 
(vg/ml) 
Infectious 
titer 
(TCID50) 
(IU/ml) 
A 1 2.68x1011 3.60x1011 1.65x1011 
 2 2.08x1011 4.58x1011 1.36x1011 
 3   2.46x1011 1.36x1011 
B 1 5.39x1013 3.47x1012  
 2 9.11x1013 4.73x1012  
C 1 8.25x1011 5.53x1011 9.28x109 
 2 5.68x1011 3.39x1011 9.28x109 
 3   3.42x1011 1.12x1010 
D 1 6.03x1011 5.19x1011 2.00x109 
 2 8.90x1011 8.50x1011 1.65x109 
E 1 4.88x1011 6.32x1011 1.65x109 
 2 5.53x1011 3.00x1011 1.82x109 
F 1 4.57x1011 7.71x1010 5.22x109 
 2 3.81x1011 7.58x1010 4.74x109 
 3   8.14x1010  
G 1 8.08x1011 1.18x1012 3.23x109 
 2 4.73x1011 1.02x1012 5.22x109 
 3   9.60x1011 4.74x109 
H 1   3.10x1012 6.32x108 
 2   2.64x1012 2.42x108 
I 1 6.26x1011 9.56x1011 6.32x108 
 2 7.40x1011 8.25x1011 4.31x108 
 3   7.19x1011  
 4   4.86x1011  
 5   5.39x1011  
J 1   2.24x1012  
 2   2.40x1012  
K 1 4.77x1011 7.02x1010  
 2 5.52x1011 4.65x1010  
L 1 4.35x1011 7.45x1011 5.22x108 
 2 4.13x1011 3.29x1011  
 3   8.79x1011  
 4   4.20x1011  
M 1 3.17x1011 7.06x1011 1.65x109 
 2 2.45x1011 8.58x1011 9.28x108 
 3   5.28x1011  
 4   2.26x1011  
N 1 1.09x1012 1.55x1011 1.12x109 
 2 8.73x1011 1.57x1011 4.31x108 
O 1 6.22x1011 2.61x1012 5.75x108 
 2 6.22x1011 3.53x1012 3.56x108 
P 1 3.19x1011 2.59x1011 6.32x108 
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Table 3.  rAAV8 
Reference Standard Material Raw Characterization data  
  
 2 4.51x1011 3.73x1011 2.67x108 
 3  3.48x1011 9.28x108 
Mean  5.50x1011 9.62x1011 2.67x109 
SD  2.20x1011 1.10x1012 3.32x109 
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Table 4. Final rAAV8 Reference Standard Material titer estimates after transformation and modeling 
 
Titer units Transformation Mean 
Lower 95% 
confidence 
limit 
for the mean 
Upper 95% 
confidence 
limit 
for the mean 
± 2 SD 
Particles (pt) 
/ml 
None 5.5 x1011 4.26x1011 6.75x1011 1.06x1011– 9.94x1011 
Vector 
genomes 
(vg)/ml 
Log10 5.75x10
11 3.05x1011 1.09x1012 4.57x1010– 7.24x1012 
Infectious 
units (IU) /ml 
Log10 
 
1.26x109 6.46x108 2.51x109 1.32x108– 1.20x1010 
 
 
 
 
 
Table 4. Final rAAV8 Reference Standard Material Titer Estimates after Transformation and Modeling 
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Table 5.Titration by qPCR AAV2RSM vs AAV8RSM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
According to Lock et al. AAV2RSM qPCR titer with 95% confidence limits is 
2.70x10
10  
vg/ml-4.75X10
10
 vg/ml 
According to table 4 in this paper AAV8RSM qPCR titer with 95% confidence is 3.05x10
11 
vg/ml-1.09x10
12
 vg/ml 
 
 
Table 5. Titration by qPCR AAV2RSM vs AAV8RSM 
 
 
 
   
Laboratory Replicate 
Genome titer 
AAV2RSM 
(qPCR) 
(vg/ml) 
Genome titer 
AAV8RSM 
(qPCR) 
(vg/ml) 
A 1 2.37x1010 7.91x1011 
 2 1.37x1010 4.86x1011 
 3 2.83x1010 5.39x1011 
 mean 2.19x1010 6.05x1011 
B 1 3.14x1010 5.28x1011 
 2 2.03x1010 2.26x1011 
 mean 2.58x1010 3.77x1011 
C 1 1.56x1011 4.55x1012 
 2 2.60x1011 6.20x1012 
C’ 1’ 3.18x1010 5.76x1011 
 2’ 3.11x1010 5.58x1011 
 3’ 3.40x1010 5.60x1011 
 mean 3.23x1010 5.64x1011 
D 1 2.00x1010 4.10x1011 
 2 3.80x1010 4.20x1011 
 3 4.00x1010 9.10x1011 
 mean 3.26x1010 5.80x1011 
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Figure Legends 
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Figure 1. Flow chart showing the steps of rAAV8RSM manufacturing. Note the pictures on the right showing the empty and full vector particles 
bands at the first and second CsCl gradient step. MCB, Master cell bank, PEG, polyethylene glycol, QC, quality control. 
 
  
 Page 39 of 50 
H
um
an
 G
en
e 
Th
er
ap
y
M
an
uf
ac
tu
rin
g 
an
d 
Ch
ar
ac
te
riz
at
io
n 
of
 a
 R
ec
om
bi
na
nt
 A
de
no
-A
ss
oc
ia
te
d 
V
iru
s T
yp
e 
8 
Re
fe
re
nc
e 
St
an
da
rd
 M
at
er
ia
l (
do
i: 1
0.1
08
9/h
um
.20
14
.05
7)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
40 
40 
 
 
 Page 40 of 50
H
um
an
 G
en
e 
Th
er
ap
y
M
an
uf
ac
tu
rin
g 
an
d 
Ch
ar
ac
te
riz
at
io
n 
of
 a
 R
ec
om
bi
na
nt
 A
de
no
-A
ss
oc
ia
te
d 
V
iru
s T
yp
e 
8 
Re
fe
re
nc
e 
St
an
da
rd
 M
at
er
ia
l (
do
i: 1
0.1
08
9/h
um
.20
14
.05
7)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
41 
41 
 
 
Figure 2. The rAAV8RSM was run on SDS PAGE gels under both denaturating and native conditions and then stained with a) Silver stain and b) 
Sypro Ruby.  In house rAAV standard was run as a positive control and buffer as a negative control.  The lanes for each gel are 1)  Benchmark 
Ladder  (unstained or prestained) – Reduced;  2) Negative Control – Reduced; 3) AAV8 Reference Material – Reduced;  4) empty , 5) Positive 
Control – Reduced;  6) Benchmark Ladder (unstained or prestained) – Native;  7) Negative Control – Native; 8) AAV Reference Material – 
Native; 9) empty, 10) Positive Control – Native. 
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Figure 3. The rAAV2RSM and rAAV8RSM were run on SDS PAGE gels under denaturating conditions and then stained with Sypro Ruby. 
Several decreasing amounts of vector particles (pt) of a reference rAAV8 vector (WL217S) were loaded as standard curve (lanes 2-6).  Different 
amounts (10
10
 pt or 5x10
9 
pt, lanes 7-8 or 9-10, respectively) of rAAV2RSM (lane 7 and 9) and rAAV8RSM (lane 8 and 10) were loaded on a gel 
according to a particle titer of 9.1x10
11 
pt/ml for rAAV2RSM (mean titer published by Lock et al) and 4.2x10
11 
pt/ml for the rAAV8RSM (titer 
calculated by this lab using the ELISA AAV8). 
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Supplementary Table 1. Vector genome titer of sub-lots produced at Nantes. 
 
 Dot blot hybridization qPCR (n=2)* 
#sub-lot Titer (vg/ml) Volume (ml) Titer (total vg) Titer (vg/ml) 
N1 1.29x1013 1.85 2.38x1013 3.91x1013 
N2 1.20x1013 2.00 2.40x1013 1.54x1013 
N3 1.68x1013 1.25 2.10x1013 4.64x1013 
N4 4.81x1012 2.68 1.29x1013 2.17x1013 
N5 2.80x1013 2.28 6.40x1013 5.19x1013 
N6 8.22x1012 2.62 2.16x1013 3.95x1013 
N7 1.30x1013 1.35 1.80x1013 3.39x1013 
N8 3.10x1013 1.81 5.60x1013 4.28x1013 
N9 7.72x1012 1.78 1.37x1013 3.56x1013 
N10 1.60x1012 1.44 2.30x1013 3.38x1013 
N11 2.50x1013 1.50 3.80x1013 3.40x1013 
N12 9.21x1012 1.63 1.50x1013 3.83x1013 
TOTAL 22.19 3.31x1014 7.90x1014 
*Internal qPCR control AAV2RSM (ATCC#VR-1616): 3.40x10
10 
vg/ml 
 
  
 Page 45 of 50 
H
um
an
 G
en
e 
Th
er
ap
y
M
an
uf
ac
tu
rin
g 
an
d 
Ch
ar
ac
te
riz
at
io
n 
of
 a
 R
ec
om
bi
na
nt
 A
de
no
-A
ss
oc
ia
te
d 
V
iru
s T
yp
e 
8 
Re
fe
re
nc
e 
St
an
da
rd
 M
at
er
ia
l (
do
i: 1
0.1
08
9/h
um
.20
14
.05
7)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
46 
46 
 
 
Supplementary Table 2 . Vector genome titer of sub-lots produced at Barcelone. 
 
 Titer qPCR SV40polyA AAV2RSM* 
#sub-lot Titer (vg/ml) Volume (ml) Titer (total vg) Titer (vg/ml) 
BCN1 1.70x1013 1.90 3.20x1013 1.90x1010 
BCN2 1.88x1013 1.50 2.82x1013 2.50x1010 
BCN3 2.52x1013 1.40 3.52x1013 2.81x1010 
BCN4 2.37x1011 0.90 2.13x1011 2.81x1010 
BCN5 5.95x1012 1.15 6.80x1012 1.90x1010 
BCN6 6.20x1012 1.35 8.40x1012 1.90x1010 
BCN7 5.15x1012 1.05 5.40x1012 3.07x1010 
BCN8 1.32x1013 1.30 1.70x1013 3.07x1010 
BCN9 9.80x1013 1.20 1.17x1013 3.07x1010 
BCN10 8.13x1012 1.20 9.76x1012 2.50x1010 
BCN11 5.31x1012 1.20 6.37x1012 2.50x1010 
BCN12 1.31x1013 0.88 1.15x1013 2.81x1010 
BCN13 9.96x1012 1.10 1.09x1013 2.52x1010 
BCN14 3.35x1012 0.90 3.00x1012 2.52x1010 
BCN15 8.49x1012 0.85 7.22x1012 2.52x1010 
TOTAL 17.88 1.93x1014  
*Internal control AAV2RSM (ATCC#VR-1616) was used in each independent qPCR 
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Supplementary Table 3. Summary statistics for the untransformed and transformed 
variables. 
  
Titer Variable N Median Mean Skewness Kurtosis 
Particles 
/ml 
Untransformed 26 5.20x1011 5.50x1011 0.612 0.0626 
Log 10 26 11.715 11.706 -0.319 -0.263 
Square root 26 720768 727503 0.155 -0.348 
Vector 
genomes 
/ml 
Untransformed 44 5.34x1011 9.62x1011 1.854 2.815 
Log 10 44 11.727 11.734 -0.128 -0.251 
Square root 44 730401 856420 1.090 0.537 
Infectious 
units/ml 
Untransformed 26 1.38x109 2.66x109 1.605 1.710 
Log 10 26 9.133 9.153 0.296 -1.070 
Square root 26 37043 44450 1.003 -0.0729 
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Supplementary Table 4. rAAV8 Reference Standard Material Titer estimates after transformation 
 
Titer units Transformation Mean 
Lower 95% 
confidence 
limit 
for the mean 
Upper 95% 
confidence 
limit 
for the mean 
± 2 SD 
Particles (pt) 
/ml 
None 5.50x1011 4.62x1011 6.39x1011 1.12x1011  –  9.88x1011 
Vector 
genomes 
(vg)/ml 
Log10 5.42x10
11 3.85x1011 7.64x1011 5.68x1010  –  5.18x1012 
Infectious 
units (IU) /ml 
Log10 
 
1.42x109 8.93x108 2.27x109 1.41x108 – 1.44x1010 
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for SW28 rotor. The gradient is centrifuged at 28 000 rpm for 24 hours at 15°C. 
 
The full particles band is collected with a 
10mL syringe and transfered to a new 
UltraClear tube for SW41 rotor filled with 
1.375 density CsCl. The 2nd gradient is 
centrifuged at 38 000 rpm for 48 hours at 
15°C. The enriched-full particles band is then 
collected with a 10mL syringe. The viral 
suspension is then subjected to 4 successive 
rounds of dialysis under slight stirring in a 
Slide-a Lyzer cassette against DPBS. The 
purified vector sublot is finally collected, 
sampled for vg titer and purity assay, and 
stored at <-70°C in polypropylene low-binding 
cryovials. 
 
1st Gradient 
 
 
 
 
 
 
 
 
 
 
 
 
 
Empty 
capsids 
 
Full particles 
2
nd
 Gradient 
 
 
 
 
 
 
 
 
 
 
 
 
 
Twelve sublots were produced at the UMR649, Nantes and fourteen at UAB. All of the twenty-six 
sublots were tested for vector genome titer using Dot blot hybridization and/or Q-PCR (see table 2 and 
3) and protein purity by silver staining following SDS-Polyacrylamide gel electrophoresis (see figure 
2 and 3). The batch #BCN4 from UAB was excluded due to a titer below the specification. The batch 
#BCN7 from UAB was excluded due to the detection of a high molecular weight extra-band 
on the silver stained SDS-PAGE gel. Vector identity was confirmed by Western blot using an anti-
CAP B1 antibody (Progen origin). A Western Blot analysis using a polyclonal anti-AAV2 antibody 
(Progen origin) suggests that the extra-band below VP3 revealed by silver stain is a cleavage product 
of the capsid proteins (Van Vliet et al., MolTher 2006). Western blots were performed on N6 and N8 
sublots produced in Nantes (see figure 4).  
 
Figure 1 : AAV8-RSM sublots (Nantes), Silver Stained SDS-PAGE gel, 2.10
e
10 vg/well 
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Figure 3 : AAV8-RSM sublots (UAB), Silver Stained SDS-PAGE gel, 5.10
e
9 vg/well 
 
 
 
 
 
 
 
 
Sublot BCN7 excluded due to extra-band. 
 
Figure 4 : AAV8-RSM sublots N6 and N8, Western Blot, identity and purity analysis 
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Supplementary Figure 3 !
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Figure 5 : AAV8-RSM final product, Silver Stained SDS-PAGE gel, 1.10e10 vg/well 
 
 
 
 
 
 
 
 
 
 
 
 
Equal amount of AAV2RSS (lane 1) and AAV8RSS (lane 2) capsid proteins were loaded on the gel. 
The difference in vector genomes loaded is due to the removal of empty particles from the AAV8RSS 
by Cesium Chloride density centrifugations. The absence of AAV capsid bands on lane 3 is due to the 
lack of migration of intact capsids into the gel. 
 Prospects 
The vials  of AAV8-RSM are currently being stored at < -70°C in a secured qualified freezer at ABG. 
The stock is ready to be shipped to ATCC (the CDC permit #2010-11-082 has been obtained from Liz 
Kerrigan at ATCC) who will  store and distribute the vials to users (Ref# VR-1816). The final QC 
plan is yet to be finalized by the AAV8-RSM WG. However, it’s most likely that the QC schedule 
should be similar to the AAV2-RSM, in order to keep harmonization between the two standards. The 
same testing laboratories will be solicited and ATCC will provide them with the AAV8-RSM needed 
vials. Martin Lock (Gene Therapy Program, Dept. Pathology/Lab Med.,University of Pennsylvania) 
who beta-tested the SOPs for AAV2-RSM, has volunteered to coordinate the characterization of the 
AAV8-RSM and beta-testing the protocols. Beyond the safety assays performed by VITROLOGY, the 
QC plan includes assays for infectious titer, transducing unit titer, vector genome titer, and 
purity/identity assay (SDS-PAGE, silver stain, western blot). Furthermore, M. Lock is also currently 
developing an AAV8 specific Capsid ELISA titer assay with PROGEN Gmbh, Germany, who already 
participated on the AAV2-RSM Quality Control Subcommittee. The statistical analysis of the data 
obtained from the different testing labs is planned to be conducted at the University of Florida, as was 
previously performed for the AAV2-RSM. A stability study will also be conducted on an annual basis, 
including, at least the following assays: (i) infectious titer, (ii) transducing titer, (iii) vector genome 
titer and (iv) capsid integrity. 
 
1: AAV2RSS (1,5.109 vg) Reduced 
2: AAV8RSS (1.1010 vg) Reduced 
3: AAV8RSS (1.1010 vg) Native 
250 kDa 
150 kDa 
100 kDa 
75 kDa 
 
 
50 kDa 
 
37 kDa 
 
25 kDa 
L     1        2      3 
1:	  AAV2RSM	  (1.5x109	  vg)	  denaturated	  
2:	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